Symptom improvement and residual symptoms during acute antidepressant treatment in pediatric major depressive...

Area of Science:

• Child and Adolescent Psychiatry
• Pharmacological Treatments
• Mental Health Research

Background:

• Understanding the trajectory of depressive symptom improvement is crucial for effective treatment planning in pediatric major depressive disorder (MDD).
• Identifying symptoms that persist despite acute treatment can guide clinicians in providing targeted interventions.
• Fluoxetine is a commonly prescribed selective serotonin reuptake inhibitor for pediatric depression.

Purpose of the Study:

• To investigate the timing of depressive symptom improvement during acute fluoxetine treatment in youths.
• To identify common residual depressive symptoms after 4, 8, and 12 weeks of treatment.
• To inform clinical practice regarding monitoring and intervention for persistent symptoms.

Main Methods:

• Prospective, open-label study of 168 children and adolescents (aged 7-18) with MDD.
• 12 weeks of fluoxetine treatment.
• Symptom assessment using the Kiddie Schedule for Affective Disorders and Schizophrenia and the Children's Depression Rating Scale-Revised.

Main Results:

• Significant improvement in all depressive symptoms was observed, particularly within the first 4 weeks of treatment.
• After 12 weeks, 47% of patients who achieved remission still reported at least one residual symptom.
• The most frequent residual symptoms included impaired school performance, insomnia, and irritability.

Conclusions:

• Residual depressive symptoms are prevalent in pediatric patients even after 12 weeks of fluoxetine treatment, including those who have achieved remission.
• Clinicians should closely monitor symptom progression and consider additional interventions for persistent symptoms like insomnia and difficulties with school performance.
• Early identification of treatment-resistant symptoms is essential for optimizing outcomes in depressed youth.